Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Nephrology, Dokuz Eylul University, School of Medicine, Balcova, Izmir, Turkey.
Acute humoral rejection (AHR) is generally less responsive to conventional anti-rejection treatment with consequent allograft losses. Therapeutic options include antilymphocyte antibody (ATG), intravenous immunglobulin (IVIG), plasmapheresis, or immunoadsorption with protein A together with intensification of immunsuppression with a tacrolimus/mycophenolate mofetil combination. This report describes a transplant recipient who responded to rituximab therapy as treatment for steroid-, ATG-, IVIG-, and plasmapheresis-resistant AHR.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on